600161 · SSE · China
tiantanbio.comFinancials as of FY2025
Collects blood plasma from Chinese donors and turns it into medicines that Chinese hospitals are required by law to buy domestically.
What this company is and how it runs — written from structure, not news.
Beijing Tiantan Biological Products collects human plasma from a network of NMPA-approved donor centres across China and processes it into albumin, immunoglobulins, and clotting factors at licensed fractionation facilities — a chain that Chinese regulations require to run entirely on domestic plasma, with no imports permitted. Because NMPA approvals for collection centres and for the fractionation plants that process their output are granted together against a validated domestic supply chain, a new competitor cannot simply build a plant and source plasma elsewhere — both licences depend on each other, and neither can be obtained independently. Every finished lot must then clear a batch-release review that ties the product back to its donor provenance before hospitals can buy it, and because hospital procurement systems track those NMPA lot numbers, switching to an alternative supplier would require a full revalidation process that most hospitals have no reason to undertake. The same regulatory structure that locks out competitors also caps how far the business can grow: NMPA limits how often donors can give and how many collection centres can be approved, so no amount of investment in fractionation equipment can raise plasma output beyond what licensed donors are permitted to supply — and if Beijing ever revised the import ban, a foreign fractionator with larger plasma pools could enter the market overnight without needing any of that domestic network.
How does this company make money?
The company sells plasma-derived medicines and vaccines to Chinese hospitals on a per-unit basis through provincial tender processes. Prices are not set freely — they are negotiated with the National Healthcare Security Administration and governed by government procurement contracts, so the company operates within state-determined price bands for most of what it sells.
What makes this company hard to replace?
Hospital procurement systems are built around NMPA lot tracking, and accepting a different supplier's products would require a complete revalidation process — a significant administrative and regulatory burden. Vaccine cold-chain distribution networks are calibrated to the exact formulations this company produces, so swapping products is not straightforward. Provincial health authorities also maintain standing preferred-supplier relationships for emergency stockpiling, which further embeds the company in local procurement decisions.
What limits this company?
The NMPA controls how often donors can give plasma and how many collection centres can operate and where. That means the total volume of plasma available to fractionate is set by regulation, not by how much money the company invests or how many factories it builds. Adding more equipment does not help if there is no additional plasma to process.
What does this company depend on?
The company cannot run without human plasma from NMPA-approved collection centres inside China, NMPA batch release approvals for each finished product lot, cold-chain logistics infrastructure to move temperature-sensitive products, and provincial hospital procurement contracts that provide the actual sales channel.
Who depends on this company?
Chinese hospitals depend on this company for immunoglobulin supplies used to treat patients with weakened immune systems — if supply stopped, those patients would face shortages with no domestic alternative. China's hepatitis B vaccination programme depends on domestic vaccine supply to hit its population immunity targets. Haemophilia treatment centres across China depend on the clotting factors this company produces from locally sourced plasma.
How does this company scale?
The vaccine side of the business can grow by adding bioreactor capacity and automated filling lines, which is a straightforward capital investment. Plasma fractionation cannot grow the same way — output is capped by how much plasma NMPA-approved Chinese donors are permitted to supply, so that half of the business hits a hard ceiling no matter how much is spent on equipment.
What external forces can significantly affect this company?
China's national pharmaceutical self-sufficiency policies currently protect this business by banning imported plasma, but a policy reversal under U.S.-China trade pressure or a WTO dispute could open the market to foreign competitors overnight. An ageing Chinese population is pushing demand for immunoglobulin therapies up faster than the donor pool can grow, tightening the supply constraint further. U.S.-China trade tensions also affect access to the specialised biomanufacturing equipment the company needs to expand.
Where is this company structurally vulnerable?
If the NMPA changed its rules to allow imported plasma — because of a trade agreement, a WTO ruling, or a domestic shortage that forced a policy shift — foreign companies with much larger plasma supplies and lower costs per litre could enter China without needing to build a domestic collection network at all. That one regulatory change would remove the barrier the entire business rests on.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: the fast moving average sits below the slow moving average, the company has been profitable for three years, and cash-flow margin is elevated.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is in the upper part of its industry's equity-to-assets range.
Three observations co-occur: the 14-period weekly RSI is at or below 30 (recent weekly losses outpacing gains), the company has been profitable for each of the last three annual periods, and the equity ratio is elevated. The configuration describes co-occurring readings; the conventional 'oversold' or 'selling pressure' framings of the RSI observations are not endorsed.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and book value has increased every year for four years. The set describes a depressed-price profile alongside fundamental stability and equity accumulation.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and the equity ratio is in the elevated industry-benchmarked range. The configuration describes a depressed-price, profitable, equity-funded profile.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph